BOOK
PET Imaging in the Management of Neuroendocrine Tumors, An Issue of PET Clinics, E-Book
Stefano Fanti | Cristina Nanni | Richard P. Baum
(2014)
Additional Information
Book Details
Abstract
Nuclear Medicine has greatly contributed to the diagnosis and treament of neuroendocrine neoplasms. This issue of PET Clinics will focus not only on the diagnosis and treatment of neuroendocrine tumors, but also theranostics. Topics include SPECT and other PET tracers, F-DOPA, Ga-DOTA-peptides, Yttrium- and Lutetium-based therapy, and the role of FDG PET. It also covers key information of theranostics.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| PET Imaging in the Management of Neuroendocrine Tumors | i | ||
| Copyright | ii | ||
| Contributors | iii | ||
| Contents | v | ||
| PET Clinics | viii | ||
| CME Page\r | ix | ||
| Section I: Nuclear Medicine in the Diagnosis and Treatment of Neuroendocrine Neoplasms | A1 | ||
| Nuclear Medicine Procedures in the Diagnosis of NET | 1 | ||
| Key points | 1 | ||
| Neuroendocrine tumors: a clinical point of view | 1 | ||
| Pathologic Setting | 1 | ||
| Epidemiology | 2 | ||
| Markers | 3 | ||
| Radiopharmaceuticals and Protocols | 3 | ||
| SPECT radiotracers | 3 | ||
| Evolution of scanner for SPECT radiotracers | 5 | ||
| PET radiotracers | 5 | ||
| Evolution of scanner for PET radiotracers | 6 | ||
| References | 7 | ||
| Single-Photon Emission Computed Tomography Tracers in the Diagnostics of Neuroendocrine Tumors | 11 | ||
| Key points | 11 | ||
| Introduction | 11 | ||
| The radiopharmaceuticals | 12 | ||
| A Metabolic Probe for the Study of NETs: Meta-131I-Benzylguanidine | 12 | ||
| SS and Its Analogues | 12 | ||
| Nuclear Medicine Receptor Imaging: an Outline | 12 | ||
| Imaging technique | 13 | ||
| mIBG Scintigraphy | 14 | ||
| Clinical indications | 14 | ||
| Precaution before examining/preparing the patient and recommendations | 14 | ||
| Radiopharmaceutical injection and recommendation after the tracer administration | 14 | ||
| Imaging acquisition | 14 | ||
| SRS | 15 | ||
| Clinical indications | 15 | ||
| Precaution before undertaking the examination/preparation of the patient and recommendations | 15 | ||
| Radiopharmaceutical injection and recommendation after tracer administration | 15 | ||
| Imaging acquisition | 15 | ||
| Imaging findings | 15 | ||
| GEP NETs | 16 | ||
| NETs of the Lung | 17 | ||
| Pheochromocytoma and Paraganglioma | 18 | ||
| Neuroblastoma | 19 | ||
| Medullary Thyroid Carcinoma | 20 | ||
| Merkel Cell Carcinoma | 20 | ||
| Thymic Carcinoids | 20 | ||
| Pituitary | 21 | ||
| Differential Diagnosis, Pitfalls | 21 | ||
| Appendix | 23 | ||
| Summary | 23 | ||
| References | 23 | ||
| 18F-Fluorodihydroxyphenylalanine in the Diagnosis of Neuroendocrine Tumors | 27 | ||
| Key points | 27 | ||
| Introduction | 27 | ||
| Imaging technique and analysis | 28 | ||
| Gastroenteropancreatic neuroendocrine tumors | 30 | ||
| Pheochromocytoma and paraganglioma | 31 | ||
| Medullary thyroid cancer | 32 | ||
| Summary | 34 | ||
| References | 35 | ||
| 68Ga-DOTA-peptides in the Diagnosis of NET | 37 | ||
| Key points | 37 | ||
| Comparison of 68Ga-DOTA-peptides with metabolic tracers | 39 | ||
| 68Ga-DOTA-peptides PET/CT imaging protocol | 39 | ||
| Pitfalls in image interpretation | 40 | ||
| Summary | 40 | ||
| References | 41 | ||
| Role of 18F-Fluorodeoxyglucose PET in the Study of Neuroendocrine Tumors | 43 | ||
| Key points | 43 | ||
| Introduction | 43 | ||
| Mechanism of 18F-FDG uptake | 44 | ||
| NETs | 44 | ||
| Enterochromaffin Cell Tumors | 45 | ||
| Sympathomedullary Tumors | 50 | ||
| MTC | 51 | ||
| References | 53 | ||
| Other PET Tracers for Neuroendocrine Tumors | 57 | ||
| Key points | 57 | ||
| Introduction | 57 | ||
| MIBG imaging the catecholamine pathway | 58 | ||
| β-[11C]-5-HTP imaging the serotonin pathway | 60 | ||
| Summary | 61 | ||
| References | 62 | ||
| Preclinical Studies of SPECT and PET Tracers for NET | 63 | ||
| Key points | 63 | ||
| Introduction | 63 | ||
| Exendin | 64 | ||
| Gastrin | 65 | ||
| Bombesin | 66 | ||
| Summary | 67 | ||
| References | 67 | ||
| Yttrium-Based Therapy for Neuroendocrine Tumors | 71 | ||
| Key points | 71 | ||
| Introduction | 71 | ||
| Radiobiologic basis of PRRT | 72 | ||
| Distinctive features of tumor irradiation | 73 | ||
| Clinical dosimetry | 73 | ||
| Safety profile | 74 | ||
| Kidney | 75 | ||
| Bone Marrow | 76 | ||
| Others | 76 | ||
| Efficacy | 77 | ||
| Final considerations | 79 | ||
| References | 80 | ||
| Section II: Theranostics of Neuroendocrine Neoplasms | A3 | ||
| Patient Selection for Personalized Peptide Receptor Radionuclide Therapy Using Ga-68 Somatostatin Receptor PET/CT | 83 | ||
| Key points | 83 | ||
| How does SUV relate with SSTR density? | 83 | ||
| Impact of 68Ga-SSTR PET/CT on management of NETs | 84 | ||
| Additional role of FDG PET/CT | 86 | ||
| Pretherapeutic SUVs and posttherapeutic response | 88 | ||
| References | 89 | ||
| Theranostics with Ga-68 Somatostatin Receptor PET/CT | 91 | ||
| Key points | 91 | ||
| Introduction | 91 | ||
| Response assessment using PET | 92 | ||
| 68Ga-somatostatin receptor PET/CT | 92 | ||
| Role of additional 18F-FDG PET/CT | 95 | ||
| Future perspectives | 95 | ||
| References | 97 | ||
| Relevance of PET for Pretherapeutic Prediction of Doses in Peptide Receptor Radionuclide Therapy | 99 | ||
| Key points | 99 | ||
| Dosimetry in radionuclide therapy | 99 | ||
| State of the Art and Controversies | 99 | ||
| Dosimetry in Peptide Receptor Radionuclide Therapy | 100 | ||
| Dosimetric Imaging in PRRT | 101 | ||
| PET imaging techniques and practices | 101 | ||
| 86Y | 101 | ||
| PET imaging of 86Y | 101 | ||
| Dosimetry based on 86Y-petides | 102 | ||
| Summaries drawn from 86Y-based dosimetry | 102 | ||
| 90Y | 103 | ||
| PET imaging of 90Y | 103 | ||
| Dosimetry based on 90Y-PET | 105 | ||
| 68Ga | 105 | ||
| Correlations of 68Ga uptake with absorbed 177Lu dose | 105 | ||
| Future perspectives | 107 | ||
| 44Sc: a New Outlook? | 108 | ||
| Summary | 108 | ||
| References | 109 | ||
| Index | 113 |